If you’ve gone down the kratom rabbit hole even a little, you’ve probably run into one phrase that keeps resurfacing: 7-hydroxymitragynine bioavailability. People read that 7-OH (or 7-HMG) is extremely potent at mu-opioid receptors, then make a quick mental leap: “More 7-OH must automatically mean a much stronger product.” It sounds logical on the surface, but once you look at the pharmacology, that neat story falls apart pretty fast. Bioavailability, metabolism, and absorption work together in slippery, non-intuitive ways that can flip simple assumptions on their head and make label claims or marketing language highly misleading if you take them at face value.
This is where understanding the science pays off. In this article, we’ll unpack what bioavailability really means, how 7-OH behaves differently from mitragynine, and which specific factors actually shape how much 7-OH your body gets to use after you swallow a dose. We’ll also tie those concepts directly to kratom lab testing, COAs, and vendor claims, so you can look at a kratom lab report and immediately see what it does, and doesn’t, tell you about 7-OH exposure. None of this is dosing advice or medical guidance; think of it instead as a practical crash course in the pharmacokinetics you need to read kratom science like an informed skeptic rather than a marketing target.
To understand why people obsess over 7-OH bioavailability, you have to zoom out and look at its place in the kratom alkaloid family. Kratom leaves contain a whole mixture of indole alkaloids, but one clearly dominates: mitragynine. That’s the main compound you’ll see on most COAs, usually making up the bulk of the total alkaloid content in traditional leaf. By contrast, 7-hydroxymitragynine is a minor player in the raw plant, often present only in very small amounts relative to mitragynine. In many cases, 7-OH in finished leaf-based products is best described as a trace component rather than a major one.
The twist is that your body doesn’t just passively receive these alkaloids; it actively transforms them. Mitragynine is metabolized in the liver, primarily by CYP3A enzymes, into several metabolites, including 7-OH. That means most of the 7-OH you see in blood after kratom use wasn’t there in the original leaf in any meaningful quantity; it was generated inside you from mitragynine. So, in practical terms, 7-OH is mostly a downstream metabolite, and mitragynine is the starting material your body uses to make it.
Now add in receptor pharmacology. Preclinical work has shown that 7-OH is a much stronger partial agonist at mu-opioid receptors than mitragynine, often several-fold more potent at the receptor level in animal models and in vitro assays. That potency at the receptor is one reason people talk about 7-OH as a “big deal,” even when its measured blood levels are low. But potency alone isn’t the whole story. You also need to know how much of that compound actually reaches systemic circulation in an active form after you take it orally. That’s where bioavailability steps into the spotlight.
Researchers studying mitragynine consistently report low-to-moderate oral bioavailability, with substantial variability both between species and among individual humans. Surprisingly, oral dosing can sometimes produce more pronounced effects than you’d expect just from looking at raw blood concentrations, which hints at complex distribution and active metabolites. For 7-OH, early pharmacokinetic work suggests very low oral bioavailability when 7-OH is given directly, on the order of a few percent in animal models, meaning only a small fraction of the ingested dose survives as the intact parent compound in circulation. When you put all that together, it becomes obvious you can’t simply compare milligrams of 7-OH on a label and assume you understand what’s happening in the body.
Strip away the jargon, and bioavailability simply answers one question: “Out of the amount I took, how much actually ended up in my bloodstream in a usable form?” For oral dosing, that number is almost never 100%, because compounds have to survive the gut environment, cross intestinal barriers, and then undergo first-pass metabolism in the liver before gaining full access to the rest of the body.
For 7-OH taken orally as a standalone compound, animal data suggest this fraction is very low. In one in vivo pharmacokinetic characterization, researchers dosed 7-OH both intravenously and orally, then compared the resulting concentration–time curves. When they did the math, they found oral bioavailability of only a few percent, even though 7-OH appeared in plasma quickly after oral dosing. That combination, rapid appearance plus very low bioavailability, points straight to extensive first-pass metabolism rather than poor absorption alone.
When you break oral bioavailability down, you’re really looking at three big checkpoints:
Absorption: How much 7-OH crosses the gut wall into portal circulation.
First-pass metabolism: How much is chewed up or transformed by enzymes in the intestinal wall and liver before it escapes into systemic circulation.
Distribution and binding: How much remains unbound and in a form that can actually interact with receptors once it’s in the blood.
For 7-OH, the available data say: absorption is relatively rapid, but metabolism is aggressive, and only a small fraction of the ingested dose survives as parent 7-OH after that gauntlet. Mitragynine runs into similar issues, but here’s the twist that matters for kratom users: some of the metabolic “loss” of mitragynine shows up as gain in 7-OH, because your body is converting one alkaloid into another. That’s why 7-OH can end up being pharmacologically important even if very little is present in the original leaf or extract.
The key idea to hold on to is this: 7-OH can be extremely potent at mu-opioid receptors yet has low oral bioavailability when consumed as a single compound. Those facts are not in conflict. In practical terms, relatively small concentrations of 7-OH in plasma, especially when formed from mitragynine, can drive a disproportionately large share of kratom’s opioid-like effects compared with what raw concentration numbers might suggest at first glance.
Once you know that mitragynine is converted into 7-OH, the “parent vs metabolite” story changes how you read both research and marketing materials. Animal and human studies have repeatedly shown that CYP3A enzymes (especially CYP3A4 in humans) are responsible for converting mitragynine to 7-OH. That’s been demonstrated in purified enzyme systems, liver microsome experiments, and actual in vivo models.
One key human experiment used a strong CYP3A4 inhibitor to stress-test that pathway. Participants were given kratom tea with a known mitragynine content, and their blood levels of mitragynine and 7-OH were tracked over time. Later, the same volunteers took the same tea after several days of pretreatment with a CYP3A4 inhibitor. When CYP3A4 was blocked, the amount of 7-OH formed from mitragynine dropped significantly, confirming that this enzyme is a major player in the conversion process in real people, not just in a test tube.
The implication is simple but powerful: when you ingest typical kratom preparations, most of the 7-OH that shows up in your blood doesn’t come directly from the leaf; your body manufactures it from mitragynine. That means “effective exposure” to 7-OH depends heavily on:
How much mitragynine is in the product?
How active your CYP3A enzymes are at that moment.
What other substances are you taking that may inhibit or induce those enzymes?
Individual differences in liver function and metabolism.
In other words, two products with identical mitragynine labels might behave differently if the user’s metabolism differs, and two people taking the same product can end up with very different 7-OH profiles in their blood. When you compare mitragynine and 7-OH side by side, you’re not just comparing two alkaloids; you’re looking at a dynamic parent–metabolite system where dose on paper and dose your body actually sees are separated by a complex metabolic filter.
You don’t have to be a pharmacologist to follow the big-picture numbers that shape 7-OH exposure, but it helps to know what researchers are talking about when they toss around terms like Tmax and AUC. Here are the essentials in plain language.
Tmax is the time it takes to reach peak blood levels after a dose. In human kratom studies, mitragynine usually peaks somewhere around an hour after ingestion, give or take, while 7-OH tends to peak a bit later, often around the 1.2–2 hour range. That delay reflects both the time required for absorption and the metabolic conversion step from mitragynine.
Cmax is the highest concentration of a drug in the blood. The absolute values differ widely between studies, but the general pattern is that mitragynine shows higher peaks than 7-OH, while 7-OH packs more punch at the receptor per unit of concentration.
AUC (area under the curve) captures total exposure over time rather than just the highest peak. It’s particularly useful when you’re comparing oral vs intravenous dosing of the same compound to calculate bioavailability, or when you’re looking at how repeated dosing might lead to accumulation.
Half-life is the time it takes for the concentration to drop by half once the compound is in circulation. Both mitragynine and 7-OH have elimination half-lives that allow them to persist for hours, which helps explain why effects don’t vanish immediately as plasma levels fall.
From a real-world perspective, you can imagine mitragynine as the first wave to hit the bloodstream, with 7-OH following as a metabolite spike. The exact height and timing of that second wave depend on your metabolic machinery. A product with modest 7-OH content but predictable mitragynine pharmacokinetics can easily give you more reliable 7-OH exposure than a flashy product with big 7-OH numbers but poorly understood absorption or metabolism. The body is doing the math here, not the label.
Once you’ve got that framework in mind, you can start to see which levers actually matter when you talk about 7-OH bioavailability in real people using real products.
On the gut absorption side, 7-OH appears to cross intestinal barriers reasonably well. In vitro permeability studies using intestinal cell models suggest that both mitragynine and 7-OH can cross these layers without being actively pumped back out by common efflux transporters. That points away from “poor absorption” as the main problem and toward metabolic loss as the main cause of low oral bioavailability.
The real action is in first-pass metabolism. As soon as an oral dose is absorbed into portal circulation, it encounters intestinal and hepatic enzymes, especially CYP3A variants, that begin to transform the compound. For 7-OH, the transformation likely involves metabolic pathways that remove or modify the parent molecule before it reaches systemic circulation in its original form. In animal studies comparing oral and intravenous 7-OH, the exposure gap was large enough to put oral bioavailability in the few-percent range, even though the compound was detected quickly after dosing.
Then there’s individual variability. CYP3A enzyme activity can be influenced by:
Genetic differences between people.
Co-administered medications like certain antifungals or antibiotics.
Dietary factors, such as grapefruit and other foods, affect enzyme activity.
Underlying liver health and overall metabolic status.
Add those variables together, and you end up with a situation where the same kratom tea can generate different 7-OH exposure profiles in different users, even at the same dose. That’s one of the reasons pharmacokinetic research has started to explore not just single-dose behavior but also multiple-dose patterns and interactions.
Finally, formulation matters. Most pharmacokinetic research uses controlled preparations, but the commercial world is packed with powders, capsules, resins, tinctures, and semi-synthetic products that claim very high 7-OH content. Changing the matrix, water-based tea, alcohol, oil, compressed tablets, can alter how quickly compounds dissolve, where they’re absorbed, and how long they remain in environments rich in enzymes. The same nominal 7-OH dose could behave quite differently depending on whether it’s in a simple tea or a concentrated extract, even before you factor in metabolism.
If you’re serious about kratom safety, COAs and third-party lab reports are non-negotiable, but they’re also often misunderstood. A standard kratom COA might list:
Mitragynine percentage or mg/g.
Measured 7-OH content, usually very low in traditional leaf.
Microbial results, heavy metal levels, and other contamination checks.
Sometimes, a broader alkaloid profile is required for more detailed products.
That data is extremely useful for confirming that a product is what it claims to be and that it meets basic safety thresholds. What they don’t do is tell you how much 7-OH will actually reach your bloodstream after you swallow that product. That jump, from “what’s in the bag” to “what’s in your blood,” is where bioavailability and metabolism take over.
Seeing trace 7-OH on a leaf COA is normal and usually not very informative on its own. Seeing unusually high 7-OH in something marketed as an extract or semi-synthetic product can be a red flag that you’re dealing with a very different risk and potency profile than traditional kratom. But in both cases, the lab numbers are just the starting point. They don’t account for enzyme activity, drug interactions, individual variability, or formulation effects.
The smartest way to use COAs is as a gatekeeper for identity and safety: confirm the alkaloid profile looks plausible for the product type, verify there are no obvious contaminants, and check that nothing unexpected has been added. Then, instead of assuming those numbers translate directly to “strength,” you mentally overlay what you know about 7-OH’s low standalone bioavailability and its dependence on mitragynine metabolism. That mental step alone will put you miles ahead of most marketing copy.
With all this nuance floating around, a few overly simple myths keep coming back, especially in marketing-heavy spaces.
Myth one: “Higher 7-OH on the COA automatically means a stronger experience.” In reality, traditional leaf carries very little natural 7-OH, and the bulk of meaningful 7-OH exposure in ordinary use comes from your body converting mitragynine. Even in products with elevated 7-OH, the combination of low oral bioavailability and heavy first-pass metabolism means you can’t just equate label percentages with predictable real-world impact.
Myth two: “7-OH bioavailability is basically the same as mitragynine’s.” The data we have so far suggest otherwise. Mitragynine has low-to-moderate oral bioavailability and can exhibit counterintuitive behavior when comparing routes of administration. 7-OH, by contrast, appears to have very low oral bioavailability when given by itself in animal models, even though it’s more potent at the receptor. The two compounds are linked, but you can’t simply transfer assumptions about mitragynine to 7-OH.
Myth three: “If 7-OH is more potent, you should push 7-OH content as high as possible in products.” That line of thinking skips over safety, ignores the complexity of metabolism, and treats potency as a single dial you can crank up without side effects. Human pharmacokinetic research on standard kratom preparations is still developing, and we already know enzyme interactions can meaningfully alter 7-OH formation. Squeezing 7-OH up to extremely high levels in semi-synthetic products essentially sidesteps some of the natural checks and balances that come from gradually metabolizing mitragynine, and that’s not automatically a good thing.
None of this is guesswork. When scientists talk about 7-OH bioavailability, they’re basing it on structured experiments. In animal studies, they administer 7-OH both intravenously and orally, then collect blood at various time points and analyze samples using methods such as LC–MS/MS. That gives them concentration–time curves for each route. Comparing total exposure (AUC) and adjusting for dose allows them to estimate absolute oral bioavailability.
In human studies, the picture is a bit more complex because people are usually consuming kratom preparations rather than pure 7-OH. Researchers still draw repeated blood samples, quantify both mitragynine and 7-OH over time, and then model the relationships between dose, plasma levels, and metabolite formation. By adding in things like enzyme inhibitors, they can tease apart which pathways are doing most of the work and how sensitive the system is to interference.
In addition to live studies, in vitro experiments using liver microsomes and isolated enzymes help map which pathways are responsible for what. Mitragynine, for example, is rapidly transformed by CYP3A4, with 7-OH appearing as a major metabolite under those conditions. 7-OH itself behaves differently, showing relative stability in some oxidative systems but vulnerability in others, and these differences help explain why the parent–metabolite relationship doesn’t look like a simple one-way street.
All of those lines of evidence, animal pharmacokinetics, human volunteer studies, and in vitro metabolism, converge on a consistent story: 7-OH is an active and potent metabolite of mitragynine, present in low amounts in natural leaf, heavily shaped by CYP3A-driven metabolism, and characterized by low oral bioavailability when given directly as a single compound.
When you put all of this together, 7-hydroxymitragynine bioavailability stops looking like one magic percentage and starts looking like a moving target shaped by chemistry, biology, and context. On paper, 7-OH is a very strong partial mu-opioid agonist. In the plant, it’s usually a trace constituent. In your body, it’s an important metabolite generated from mitragynine via enzymes that can be influenced by everything from genetics to grapefruit juice.
For anyone reading kratom COAs or evaluating vendor claims, the most important shift is mental. High 7-OH numbers on a lab report don’t automatically equate to a simple, linear increase in effect, because bioavailability and metabolism sit between the product and your receptors. A standard-looking mitragynine-dominant profile can still yield meaningful 7-OH exposure through metabolic conversion, which is why serious pharmacokinetic work focuses on the pair together instead of treating them as isolated players.
The bottom line is this: use lab testing to confirm what’s in the product and to rule out obvious safety issues, but let your understanding of 7-OH bioavailability and metabolism shape how you interpret that data. The label tells you what went into your body. Bioavailability and pharmacokinetics determine what your body actually sees.
--- Canonical: https://www.kratomtest.org/blog/7-oh-bioavailability-what-really-affects-absorption